Aliases & Classifications for Melanoma

MalaCards integrated aliases for Melanoma:

Name: Melanoma 12 36 28 51 40 41 14 69 59
Malignant Melanoma 12 28
Cutaneous Melanoma 69
Naevocarcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1909
MeSH 41 D008545
NCIt 46 C3224
KEGG 36 H00038
ICD10 32 D03.9
UMLS 69 C0025202

Summaries for Melanoma

MedlinePlus : 40 Melanoma is the most serious type of skin cancer. Often the first sign of melanoma is a change in the size, shape, color, or feel of a mole. Most melanomas have a black or black-blue area. Melanoma may also appear as a new mole. It may be black, abnormal, or "ugly looking." Thinking of "ABCDE" can help you remember what to watch for: Asymmetry - the shape of one half does not match the other Border - the edges are ragged, blurred or irregular Color - the color is uneven and may include shades of black, brown and tan Diameter - there is a change in size, usually an increase Evolving - the mole has changed over the past few weeks or months Surgery is the first treatment of all stages of melanoma. Other treatments include chemotherapy and radiation, biologic, and targeted therapies. Biologic therapy boosts your body's own ability to fight cancer. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute

MalaCards based summary : Melanoma, also known as malignant melanoma, is related to acral lentiginous melanoma and skin melanoma, and has symptoms including pruritus and exanthema. An important gene associated with Melanoma is PTEN (Phosphatase And Tensin Homolog), and among its related pathways/superpathways are Melanoma and Phospholipase-C Pathway. The drugs Erivedge and Intron A have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and brain, and related phenotypes are Decreased substrate adherent cell growth and Decreased substrate adherent cell growth

Disease Ontology : 12 A cell type cancer that has material basis in abnormally proliferating cells derives from melanocytes which are found in skin, the bowel and the eye.

Novus Biologicals : 52 Melanoma is a malignant tumor that results from uncontrolled growth of pigmented cells, called melanocytes. Several types of melanoma exist, including superficial spreading melanoma, nodular melanoma and lentigo melanoma. Melanoma diagnosis is traditionally supported by the presence of the S-100 protein marker and HMB-45, however research has determined the sensitivity and specificity of three novel antibodies as markers for melanoma: Mitf, Melan-A and tyrosinase.

PubMed Health : 59
About melanoma: We all have moles or other small lumps and bumps that are a different color to the rest of our skin. This is perfectly normal and usually nothing to worry about. It is only rarely skin cancer.Skin cancer comes in different forms. The main types are (malignant) melanoma, basal cell cancer (BCC) and squamous cell cancer (SCC). Basal cell cancer and squamous cell cancer are sometimes grouped together and referred to as non-melanoma skin cancer. Melanoma, which often looks like a very dark mole, is the most widely known type of skin cancer. This is probably because some types are dangerous and can spread very quickly throughout the body.

Related Diseases for Melanoma

Diseases related to Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 828)
# Related Disease Score Top Affiliating Genes
1 acral lentiginous melanoma 34.9 BRAF CDKN2A KIT NRAS PTEN
2 skin melanoma 34.9 BRAF CDKN2A MCAM MIA MITF NRAS
3 malignant spindle cell melanoma 34.6 KIT MITF NRAS
4 melanoma, cutaneous malignant 1 34.6 BRAF CDK4 CDKN2A GNAQ KIT MAP2K1
5 mucosal melanoma 34.3 BRAF GNAQ KIT MAGEC1 MITF NRAS
6 melanoma, uveal 34.2 BRAF CDK4 CDKN2A GNAQ MAGEA1 MIA
7 ovarian melanoma 34.0 KIT MAP2K1 NRAS PTEN
8 epithelioid cell melanoma 33.4 MCAM MITF
9 malignant conjunctival melanoma 33.3 GNAQ NRAS
10 spitz nevus 32.9 BRAF CDKN2A
11 lung cancer 32.3 BRAF CDK4 CDKN2A KIT MAGEA1 MAGEA3
12 lentigines 31.9 BRAF KIT MITF
13 ocular cancer 31.9 CDK4 CDKN2A GNAQ
14 squamous cell carcinoma 31.6 BRAF CDKN2A MAGEA1 MAGEA3 MAGEA4 PTEN
15 neurofibroma 31.1 CDKN2A KIT MITF
16 glioblastoma 31.0 BRAF CDK4 CDKN2A GPNMB PTEN
17 hepatocellular carcinoma 31.0 CDK4 CDKN2A MAGEA1 MAGEA3 MAP2K1 NRAS
18 malignant peripheral nerve sheath tumor 31.0 CDK4 CDKN2A KIT
19 glioblastoma multiforme 30.7 BRAF CDK4 CDKN2A GPNMB PTEN
20 myeloma, multiple 30.6 BRAF CDK4 CDKN2A MAGEC1
21 histiocytic sarcoma 30.3 BRAF CDKN2A PTEN
22 melanomatosis 30.2 CDKN2A GNAQ NRAS
23 endometrial cancer 30.1 BRAF CDK4 CDKN2A KIT PTEN
24 meningeal melanocytoma 29.9 CDKN2A GNAQ NRAS
25 melanoma-pancreatic cancer syndrome 12.3
26 ocular melanoma 12.3
27 digestive system melanoma 12.3
28 melanoma, cutaneous malignant 8 12.3
29 nodular malignant melanoma 12.2
30 melanoma-astrocytoma syndrome 12.2
31 intraocular melanoma 12.2
32 amelanotic melanoma 12.2
33 lentigo maligna melanoma 12.2
34 melanoma-associated retinopathy 12.2
35 superficial spreading melanoma 12.2
36 melanoma, cutaneous malignant 2 12.1
37 melanoma, cutaneous malignant 3 12.1
38 melanoma, cutaneous malignant 5 12.1
39 melanoma, cutaneous malignant 6 12.1
40 melanoma, cutaneous malignant 9 12.1
41 melanoma, cutaneous malignant 4 12.1
42 melanoma, cutaneous malignant 7 12.0
43 choroid spindle cell melanoma 12.0
44 melanoma of soft tissue 12.0
45 dysplastic nevus syndrome 12.0
46 melanoma, cutaneous malignant 10 12.0
47 iris spindle cell melanoma 12.0
48 posterior uveal melanoma 12.0
49 ciliary body spindle cell melanoma 12.0
50 primary melanoma of the central nervous system 12.0

Graphical network of the top 20 diseases related to Melanoma:



Diseases related to Melanoma

Symptoms & Phenotypes for Melanoma

UMLS symptoms related to Melanoma:


pruritus, exanthema

GenomeRNAi Phenotypes related to Melanoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 9.23 KIT
2 Decreased substrate adherent cell growth GR00193-A-2 9.23 CDK4 KIT
3 Decreased substrate adherent cell growth GR00193-A-3 9.23 BRAF CDK4
4 Decreased substrate adherent cell growth GR00193-A-4 9.23 KIT BRAF CDK4

MGI Mouse Phenotypes related to Melanoma:

43 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.34 FBN1 CDK4 CDKN2A BRAF MAGED1 GPNMB
2 homeostasis/metabolism MP:0005376 10.27 CDKN2A BRAF FBN1 CDK4 MAGED1 GPNMB
3 cardiovascular system MP:0005385 10.25 CDKN2A BRAF FBN1 CDK4 GNAQ MAP2K1
4 endocrine/exocrine gland MP:0005379 10.24 FBN1 CDK4 CDKN2A BRAF MAP2K1 KIT
5 hematopoietic system MP:0005397 10.22 CDKN2A BRAF FBN1 CDK4 GNAQ GPNMB
6 immune system MP:0005387 10.21 BRAF FBN1 CDK4 CDKN2A MAGED1 GPNMB
7 integument MP:0010771 10.18 FBN1 CDK4 CDKN2A BRAF MAGED1 MAP2K1
8 embryo MP:0005380 10.16 CDKN2A BRAF FBN1 CDK4 MAP2K1 KIT
9 craniofacial MP:0005382 10.08 BRAF FBN1 GNAQ MAP2K1 KIT NRAS
10 digestive/alimentary MP:0005381 10.07 CDKN2A BRAF CDK4 MAP2K1 KIT NRAS
11 nervous system MP:0003631 10.06 CDKN2A BRAF FBN1 CDK4 GNAQ MAGED1
12 neoplasm MP:0002006 9.97 CDK4 CDKN2A BRAF GPNMB MAP2K1 KIT
13 pigmentation MP:0001186 9.85 FBN1 CDK4 CDKN2A BRAF GPNMB KIT
14 no phenotypic analysis MP:0003012 9.8 CDKN2A FBN1 MAGED1 KIT MCAM NRAS
15 skeleton MP:0005390 9.65 CDKN2A BRAF FBN1 MAP2K1 KIT GNAQ
16 vision/eye MP:0005391 9.32 CDK4 CDKN2A BRAF MAGED1 GPNMB MAP2K1

Drugs & Therapeutics for Melanoma

PubMedHealth treatment related to Melanoma: 59

After melanoma is diagnosed, the first step is usually to try to remove it surgically. If it is already advanced or metastatic tumors have developed elsewhere, surgery is combined with other treatments such as medication or radiation.

FDA approved drugs:

(show all 11)
# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Erivedge 17 45 VISMODEGIB Genentech January 2012
2
Intron A 17 45 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
3
Keytruda 17 45 PEMBROLIZUMAB Merck September 2014
4
Mekinist 17 45 TRAMETINIB DIMETHYL SULFOXIDE GlaxoSmithKline May of 2013
5
Odomzo 17 45 SONIDEGIB PHOSPHATE Novartis Jul-15
6
Opdivo 17 45 NIVOLUMAB Bristol-Myers Squibb March 2015/ December 2014, March 2015
7
Proleukin 17 45 ALDESLEUKIN Chiron January 1998
8
Sylatron 17 45 PEGINTERFERON ALFA-2B Merck April 2011
9
Tafinlar 17 45 DABRAFENIB MESYLATE GlaxoSmithKline May 2013
10
Yervoy 17 45 IPILIMUMAB Bristol-Myers Squibb March 2011
11
Zelboraf 17 45 VEMURAFENIB Roche August of 2011

Drugs for Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 631)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
2
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 4342-03-4 5351166
3
Vindesine Approved, Investigational Phase 4 53643-48-4, 59917-39-4 40839
4
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1 347396-82-1 459903
5
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 99011-02-6 57469
6
Trametinib Approved Phase 4,Phase 3,Phase 2,Phase 1 871700-17-3 11707110
7
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
8
nivolumab Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 946414-94-4
9
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 124-94-7 31307
10
Everolimus Approved Phase 4,Phase 2,Phase 1 159351-69-6 6442177
11
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
12
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
13
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 284461-73-0 216239 406563
14
Sunitinib Approved, Investigational Phase 4,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
15
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 110942-02-4, 85898-30-2
16
Etanercept Approved, Investigational Phase 4 185243-69-0
17
Citalopram Approved Phase 4 59729-33-8 2771
18
Aminolevulinic acid Approved Phase 4,Phase 2 106-60-5 137
19
Dabrafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 44462760 44516822
20
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 60-00-4, 62-33-9 6049
21
Bortezomib Approved, Investigational Phase 4,Phase 2,Phase 1 179324-69-7 387447 93860
22
Dasatinib Approved, Investigational Phase 4,Phase 2,Phase 1 302962-49-8 3062316
23
Olaparib Approved Phase 4,Phase 1 763113-22-0 23725625
24
Palbociclib Approved, Investigational Phase 4,Phase 1,Phase 2 571190-30-2 5330286 11431660 5005498
25
Ramucirumab Approved, Investigational Phase 4,Phase 2,Phase 1 947687-13-0
26
Vorinostat Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 149647-78-9 5311
27
Ceritinib Approved Phase 4,Phase 2,Early Phase 1 1032900-25-6
28
Crizotinib Approved Phase 4,Phase 2,Phase 1 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
29
Gefitinib Approved, Investigational Phase 4 184475-35-2 123631
30
Lactitol Investigational Phase 4,Phase 1,Phase 2 585-86-4 3871
31
Lapatinib Approved March 2007, Investigational Phase 4,Phase 2 231277-92-2, 388082-78-8 208908 9941095
32 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1
34 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
35 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
36 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Analgesics Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
40 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
41 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1
42 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 1,Phase 2
43 Antirheumatic Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
44 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2
45 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
46 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
47 Antidepressive Agents Phase 4,Phase 2,Phase 3,Phase 1
48 Antidepressive Agents, Second-Generation Phase 4,Phase 2,Phase 3,Phase 1
49 Interleukin-2 Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 2380)

# Name Status NCT ID Phase Drugs
1 Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma Unknown status NCT00226473 Phase 4 Cisplatin, Vindesine, Dacarbazine (drugs)
2 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4 Ranibizumab
3 Long Term Results of Combined Transpupillary Thermotherapy (TTT) Indocyanine Green (ICG) Based Photodynamic Therapy (PDT) in Choroidal Melanoma Completed NCT01253759 Phase 4
4 Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab Completed NCT01515189 Phase 4
5 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4 etanercept
6 Post-Operative Drainage Following Lymph Node Dissection Completed NCT00324272 Phase 4 Fibrin Sealant (Tisseel) used in the Experimental Arm.
7 Evaluating the Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment Completed NCT00352885 Phase 4 Escitalopram;Placebo;IL-2
8 A Study for Lymphocele and Lymphorrhea Control Following Inguinal and Axillary Radical Lymph Node Dissection Completed NCT02476357 Phase 4
9 Surgery Versus Radiosurgery to Treat Metastatic Brain Tumors Completed NCT00075166 Phase 4
10 Effect of Topical Imiquimod on Lentigo Maligna Completed NCT01161888 Phase 4 Imiquimod
11 Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma Recruiting NCT02451488 Phase 4 GM-CSF
12 Flu Vaccine Responses in the Setting of Melanoma Treatment Recruiting NCT03315975 Phase 4
13 Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream Recruiting NCT02685592 Phase 4 5-aminolevulinic acid nanoemulsion
14 Dabrafenib and/or Trametinib Rollover Study Recruiting NCT03340506 Phase 4 dabrafenib;trametinib
15 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
16 Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies Active, not recruiting NCT02626065 Phase 4 Nivolumab
17 TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Active, not recruiting NCT02379000 Phase 4 Triamcinolone Acetonide
18 An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma Active, not recruiting NCT01898585 Phase 4 Zelboraf
19 A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. Active, not recruiting NCT02068196 Phase 4 Ipilimumab
20 Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer Active, not recruiting NCT02287675 Phase 4 Lymphoseek;Sulfur Colloid
21 Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma Not yet recruiting NCT02645149 Phase 4 Standard therapy or clinical trial;Matched targeted therapy;Trametinib and / or supportive care
22 Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1 Not yet recruiting NCT03313544 Phase 4 Nivolumab
23 HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Terminated NCT01683188 Phase 4 vemurafenib + HD IL-2
24 HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma Terminated NCT01856023 Phase 4 High Dose Interleukin-2;Ipilimumab
25 Assessment and Tracking of Long-term Alefacept Safety Terminated NCT00454701 Phase 4 Alefacept exposure
26 Genetically-informed Therapies for Patients With Metastatic Cancer Withdrawn NCT02000739 Phase 4
27 Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients Unknown status NCT01861938 Phase 2, Phase 3
28 A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Dacarbazine in the Treatment of Patients With Non-Resectable or Metastatic Stage 3 or Stage 4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of C-Kit Unknown status NCT01280565 Phase 3 masitinib;Dacarbazine
29 Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma Unknown status NCT00002767 Phase 3
30 High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma Unknown status NCT00002763 Phase 3
31 Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma Unknown status NCT00006249 Phase 3
32 Vaccine Therapy in Treating Patients With Primary Stage II Melanoma Unknown status NCT00005052 Phase 3
33 Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver Unknown status NCT00039234 Phase 3 histamine dihydrochloride
34 Vaccine Therapy for Patients With Stage III Melanoma Unknown status NCT00052130 Phase 3
35 Vaccine Therapy for Patients With Stage IV Melanoma Unknown status NCT00052156 Phase 3
36 Treatment Of Radiation Retinopathy Trial Unknown status NCT00811200 Phase 2, Phase 3 ranibizumab;triamcinolone acetonide
37 Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma Unknown status NCT00002455 Phase 3
38 Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC Unknown status NCT00779714 Phase 3 DTIC (dacarbazine);paclitaxel + cisplatin;treosulfan + cytarabine
39 Collaborative Ocular Melanoma Study (COMS) Unknown status NCT00000124 Phase 3
40 Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon Unknown status NCT00226408 Phase 3 Interferon-alpha-2b
41 Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel Unknown status NCT01272609 Phase 3 Timolol + LCP
42 18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology Unknown status NCT00207298 Phase 3
43 MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma Completed NCT00094653 Phase 3 MDX-010 (anti-CTLA4) monoclonal antibody
44 Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma Completed NCT00002882 Phase 3 Cisplatin;Dacarbazine;Vinblastine
45 Nordic Adjuvant IFN Melanoma Trial Completed NCT01259934 Phase 3 Interferon-alpha2b - 1 year;Interferon-alpha2b - 2 years
46 Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) Completed NCT01974752 Phase 3 75mg selumetinib;placebo;Dacarbazine
47 Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267) Completed NCT00091572 Phase 3 Temozolomide;Dacarbazine
48 Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma Completed NCT00072124 Phase 3 cisplatin;dacarbazine
49 GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma Completed NCT01245062 Phase 3 GSK1120212;Chemotherapy
50 Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma Completed NCT00680225 Phase 3 Ranibizumab injection and TTT - ICG based

Search NIH Clinical Center for Melanoma

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: melanoma

Genetic Tests for Melanoma

Genetic tests related to Melanoma:

# Genetic test Affiliating Genes
1 Malignant Melanoma 28
2 Melanoma 28

Anatomical Context for Melanoma

MalaCards organs/tissues related to Melanoma:

38
Skin, T Cells, Brain, Lymph Node, Lung, Liver, Breast

Publications for Melanoma

Articles related to Melanoma:

(show top 50) (show all 12371)
# Title Authors Year
1
SLURP-1 is mutated in Mal de Meleda, a potential molecular signature for melanoma and a putative squamous lineage tumor suppressor gene. ( 29231248 )
2018
2
Lichen planopilaris associated with pembrolizumab in a patient with metastatic melanoma. ( 29387763 )
2018
3
Melanoma in situ mimicking a Lichen planus-like keratosis. ( 29350666 )
2018
4
Targeting Insulin-Like Growth Factor-I and Extracellular Matrix Interactions in Melanoma Progression. ( 29330502 )
2018
5
BMI and outcomes in melanoma: more evidence for the obesity paradox. ( 29449191 )
2018
6
Predicting the incidence and timing of central nervous system disease in metastatic melanoma: Implications for surveillance and preventative therapy. ( 29332716 )
2018
7
Genome-Wide Analysis of Uveal Melanoma Metastasis-Associated LncRNAs and Their Functional Network. ( 29240458 )
2018
8
Genome-Wide Screen for MicroRNAs Reveals a Role for miR-203 in Melanoma Metastasis. ( 29104160 )
2018
9
HLA Class I Antigen Expression in Conjunctival Melanoma Is Not Associated With PD-L1/PD-1 Status. ( 29450544 )
2018
10
Widespread finger skin metastases of melanoma. ( 29445498 )
2018
11
Localized pretibial bullous pemphigoid arising in a patient on pembrolizumab for metastatic melanoma. ( 29389067 )
2018
12
Adjuvant Therapy in Resected Melanoma. ( 29446283 )
2018
13
Analysis of survival of patients treated with vemurafenib, ipilimumab and dabrafenib for advanced skin melanoma in daily clinical practice (Real-World Data): retrospective analysis of patients treated under drug/reimbursement programmes in Poland in 2013-2016. ( 29120964 )
2018
14
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. ( 29449192 )
2018
15
Approaches to regional lymph node metastasis in patients with head and neck mucosal melanoma. ( 29044491 )
2018
16
Prognostic features for acral lentiginous melanoma. ( 29441559 )
2018
17
MRI-based treatment planning and dose delivery verification for intraocular melanoma brachytherapy. ( 28818442 )
2018
18
Senescence-associated secretory factors induced by cisplatin in melanoma cells promote non-senescent melanoma cell growth through activation of the ERK1/2-RSK1 pathway. ( 29449532 )
2018
19
Primary orbital melanoma: a case series and literature review. ( 29388848 )
2018
20
Comparative genomics reveals that loss of lunatic fringe (LFNG) promotes melanoma metastasis. ( 29193607 )
2018
21
Immunocryosurgery as monotherapy for lentigo maligna or combined with surgical excision for lentigo maligna melanoma. ( 29430695 )
2018
22
Title ultrasound features of ovarian melanoma metastases: The "Golf ball" aspect. ( 29198556 )
2018
23
Gene expression screening identifies CDCA5 as a potential therapeutic target in acral melanoma. ( 29452217 )
2018
24
MiR-767 promoted cell proliferation in human melanoma by suppressing CYLD expression. ( 29054757 )
2018
25
Primary orbital melanoma treated with orbital exenteration and postoperative radiotherapy: A case report and review of the literature. ( 29394463 )
2018
26
Get with the Program! Stemness and Reprogramming in Melanoma Metastasis. ( 29273143 )
2018
27
Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series. ( 29406396 )
2018
28
Genetic variants in the metzincin metallopeptidase family genes predict melanoma survival. ( 28796414 )
2018
29
Patient with confirmed LEOPARD syndrome developing multiple melanoma. ( 29445579 )
2018
30
Acute autoimmune myocarditis and hepatitis due to ipilimumab monotherapy for malignant melanoma. ( 29444608 )
2018
31
Distinguishing Neurofibroma From Desmoplastic Melanoma: The Value of p53. ( 29112020 )
2018
32
Intermittent hypoxia promotes melanoma lung metastasis via oxidative stress and inflammation responses in a mouse model of obstructive sleep apnea. ( 29433520 )
2018
33
Analysis of TSC1 mutation spectrum in mucosal melanoma. ( 29185092 )
2018
34
Clinical patterns and management of primary mucosal melanoma: a single centre experience. ( 29388353 )
2018
35
Adjuvant Therapy in Resected Melanoma. ( 29446288 )
2018
36
Whole-exome sequencing of oral mucosal melanoma reveals mutational profile and therapeutic targets. ( 29230811 )
2018
37
Capsule Commentary on Robinson et al.: A Randomized Trial on the Efficacy of Mastery Learning on Primary Care Providers' Melanoma Opportunistic Screening Skills and Practice. ( 29450688 )
2018
38
Reevaluation of established and new criteria in differential diagnosis of Spitz nevus and melanoma. ( 29417221 )
2018
39
Adjuvant Therapy in Resected Melanoma. ( 29446285 )
2018
40
Pyoderma Gangrenosum Under Dabrafenib and Trametinib for Metastatic Melanoma. ( 29362816 )
2018
41
The Adhesion G-Protein-Coupled Receptor, GPR56/ADGRG1, Inhibits Cell-Extracellular Matrix Signaling to Prevent Metastatic Melanoma Growth. ( 29450192 )
2018
42
Computed tomography-guided minimally invasive selective approach of an isolated retroperitoneal melanoma metastasis. ( 29154516 )
2018
43
Reply to "melanoma pattern of care in ontario: A call for strategic alignment of multidisciplinary care)". ( 29448298 )
2018
44
High density of M2-macrophages in acral lentiginous melanoma compared to superficial spreading melanoma. ( 29415335 )
2018
45
Noninvasive Gene Expression Testing in Amelanotic Melanoma. ( 29238803 )
2018
46
TR47, a PAR1-based peptide, inhibits melanoma cell migration inA vitro and metastasis inA vivo. ( 29196264 )
2018
47
Primary central nervous system malignant melanoma with leptomeningeal melanomatosis: a case report and review of the literature. ( 28986666 )
2018
48
Updates in the management of sinonasal mucosal melanoma. ( 29095708 )
2018
49
PHLPP1 mediates melanoma metastasis suppression through repressing AKT2 activation. ( 29391600 )
2018
50
Amelanotic melanoma arising within a lesion of disseminated superficial actinic porokeratosis: An unusual presentation leading to a novel therapeutic approach. ( 28976625 )
2018

Variations for Melanoma

ClinVar genetic disease variations for Melanoma:

6 (show top 50) (show all 106)
# Gene Variation Type Significance SNP ID Assembly Location
1 PTEN NM_000314.6(PTEN): c.633C> A (p.Cys211Ter) single nucleotide variant Pathogenic rs121909232 GRCh37 Chromosome 10, 89712015: 89712015
2 PTEN NM_000314.6(PTEN): c.55G> A (p.Asp19Asn) single nucleotide variant Pathogenic rs121909233 GRCh37 Chromosome 10, 89624281: 89624281
3 PTEN NM_000314.6(PTEN): c.649G> A (p.Val217Ile) single nucleotide variant Pathogenic rs121909234 GRCh37 Chromosome 10, 89717624: 89717624
4 HRAS NM_005343.3(HRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
5 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
6 KIT NM_000222.2(KIT): c.1676T> A (p.Val559Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913517 GRCh37 Chromosome 4, 55593610: 55593610
7 KIT NM_000222.2(KIT): c.2446G> T (p.Asp816Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913506 GRCh37 Chromosome 4, 55599320: 55599320
8 KIT NM_000222.2(KIT): c.2446G> C (p.Asp816His) single nucleotide variant Pathogenic/Likely pathogenic rs121913506 GRCh37 Chromosome 4, 55599320: 55599320
9 KIT NM_000222.2(KIT): c.1676T> C (p.Val559Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913517 GRCh37 Chromosome 4, 55593610: 55593610
10 KIT NM_000222.2(KIT): c.1924A> G (p.Lys642Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913512 GRCh37 Chromosome 4, 55594221: 55594221
11 NRAS NM_002524.4(NRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121434595 GRCh37 Chromosome 1, 115258745: 115258745
12 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
13 NRAS NM_002524.4(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121434596 GRCh37 Chromosome 1, 115258744: 115258744
14 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic/Likely pathogenic rs113488022 GRCh37 Chromosome 7, 140453136: 140453136
15 BRAF NM_004333.4(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913364 GRCh37 Chromosome 7, 140453134: 140453134
16 BRAF NM_004333.4(BRAF): c.1790T> G (p.Leu597Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913366 GRCh37 Chromosome 7, 140453145: 140453145
17 BRAF NM_004333.4(BRAF): c.1789C> G (p.Leu597Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913369 GRCh37 Chromosome 7, 140453146: 140453146
18 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913357 GRCh37 Chromosome 7, 140481403: 140481403
19 BRAF NM_004333.4(BRAF): c.1781A> G (p.Asp594Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913338 GRCh37 Chromosome 7, 140453154: 140453154
20 BRAF NM_004333.4(BRAF): c.1406G> A (p.Gly469Glu) single nucleotide variant Pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
21 CTNNB1 NM_001904.3(CTNNB1): c.95A> G (p.Asp32Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913396 GRCh37 Chromosome 3, 41266098: 41266098
22 CTNNB1 NM_001904.3(CTNNB1): c.110C> T (p.Ser37Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 GRCh37 Chromosome 3, 41266113: 41266113
23 CTNNB1 NM_001904.3(CTNNB1): c.134C> T (p.Ser45Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913409 GRCh37 Chromosome 3, 41266137: 41266137
24 CTNNB1 NM_001904.3(CTNNB1): c.133T> C (p.Ser45Pro) single nucleotide variant Pathogenic/Likely pathogenic rs121913407 GRCh37 Chromosome 3, 41266136: 41266136
25 NRAS NM_002524.4(NRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913237 GRCh37 Chromosome 1, 115258747: 115258747
26 BRAF NM_004333.4(BRAF): c.1796C> T (p.Thr599Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913375 GRCh37 Chromosome 7, 140453139: 140453139
27 BRAF NM_004333.4(BRAF): c.1799T> G (p.Val600Gly) single nucleotide variant Pathogenic rs113488022 GRCh37 Chromosome 7, 140453136: 140453136
28 NRAS NM_002524.4(NRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913250 GRCh37 Chromosome 1, 115258748: 115258748
29 NRAS NM_002524.4(NRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913250 GRCh37 Chromosome 1, 115258748: 115258748
30 NRAS NM_002524.4(NRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913237 GRCh37 Chromosome 1, 115258747: 115258747
31 NRAS NM_002524.4(NRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs121434595 GRCh37 Chromosome 1, 115258745: 115258745
32 RAF1 NM_002880.3(RAF1): c.769T> C (p.Ser257Pro) single nucleotide variant Likely pathogenic rs727505017 GRCh37 Chromosome 3, 12645700: 12645700
33 MAP2K1 NM_002755.3(MAP2K1): c.371C> T (p.Pro124Leu) single nucleotide variant Pathogenic/Likely pathogenic rs397516792 GRCh37 Chromosome 15, 66729163: 66729163
34 MAP2K1 NM_002755.3(MAP2K1): c.199G> A (p.Asp67Asn) single nucleotide variant Pathogenic rs727504317 GRCh37 Chromosome 15, 66727483: 66727483
35 FBN1 NM_000138.4(FBN1): c.5788+5G> A single nucleotide variant Pathogenic rs193922219 GRCh37 Chromosome 15, 48738898: 48738898
36 BRAF NM_004333.4(BRAF): c.1780G> A (p.Asp594Asn) single nucleotide variant Pathogenic/Likely pathogenic rs397516896 GRCh37 Chromosome 7, 140453155: 140453155
37 BRAF NM_004333.4(BRAF): c.1798G> A (p.Val600Met) single nucleotide variant Pathogenic/Likely pathogenic rs121913378 GRCh37 Chromosome 7, 140453137: 140453137
38 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913254 GRCh37 Chromosome 1, 115256530: 115256530
39 BRAF NM_004333.4(BRAF): c.1790T> A (p.Leu597Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121913366 GRCh37 Chromosome 7, 140453145: 140453145
40 NRAS NM_002524.4(NRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121913250 GRCh37 Chromosome 1, 115258748: 115258748
41 BRAF NM_004333.4(BRAF): c.1785T> G (p.Phe595Leu) single nucleotide variant Pathogenic rs121913341 GRCh37 Chromosome 7, 140453150: 140453150
42 BRAF NM_004333.4(BRAF): c.1785T> A (p.Phe595Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913341 GRCh37 Chromosome 7, 140453150: 140453150
43 BRAF NM_004333.4(BRAF): c.1783T> C (p.Phe595Leu) single nucleotide variant Pathogenic/Likely pathogenic rs794729219 GRCh37 Chromosome 7, 140453152: 140453152
44 STK11 NM_000455.4(STK11): c.580G> T (p.Asp194Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913315 GRCh37 Chromosome 19, 1220487: 1220487
45 NRAS NM_002524.4(NRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913237 GRCh38 Chromosome 1, 114716126: 114716126
46 MAP2K1 NM_002755.3(MAP2K1): c.171G> T (p.Lys57Asn) single nucleotide variant Pathogenic/Likely pathogenic rs869025608 GRCh38 Chromosome 15, 66435117: 66435117
47 NRAS NM_002524.4(NRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
48 NRAS NM_002524.4(NRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs121913255 GRCh37 Chromosome 1, 115256528: 115256528
49 BRAF NM_004333.4(BRAF): c.1390G> A (p.Gly464Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913349 GRCh37 Chromosome 7, 140481418: 140481418
50 NRAS NM_002524.4(NRAS): c.183A> C (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs121913255 GRCh37 Chromosome 1, 115256528: 115256528

Cosmic variations for Melanoma:

9 (show top 50) (show all 110)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM43690 TP53 skin,NS,malignant melanoma,superficial spreading c.592G>A p.E198K 6
2 COSM10656 TP53 skin,NS,malignant melanoma,superficial spreading c.742C>T p.R248W 6
3 COSM44026 TP53 skin,NS,malignant melanoma,superficial spreading c.559G>A p.G187S 6
4 COSM10867 TP53 skin,NS,malignant melanoma,nodular c.797G>A p.G266E 6
5 COSM125734 RAC1 skin,NS,malignant melanoma,superficial spreading c.85C>T p.P29S 6
6 COSM5111 PTEN skin,NS,malignant melanoma,superficial spreading c.737C>T p.P246L 6
7 COSM5142 PTEN skin,NS,malignant melanoma,superficial spreading c.112C>T p.P38S 6
8 COSM5119 PTEN skin,NS,malignant melanoma,nodular c.730C>T p.P244S 6
9 COSM231631 PREX2 skin,NS,malignant melanoma,nodular c.468G>A p.K156K 6
10 COSM231663 PREX2 skin,NS,malignant melanoma,superficial spreading c.4165G>A p.E1389K 6
11 COSM231651 PREX2 skin,NS,malignant melanoma,nodular c.2323C>T p.P775S 6
12 COSM6503475 PREX2 skin,NS,malignant melanoma,nodular c.1091A>T p.K364I 6
13 COSM231647 PREX2 skin,NS,malignant melanoma,nodular c.1994C>T p.P665L 6
14 COSM6503481 PREX2 skin,NS,malignant melanoma,nodular c.702G>A p.W234* 6
15 COSM6503482 PREX2 skin,NS,malignant melanoma,superficial spreading c.934G>A p.D312N 6
16 COSM231665 PREX2 skin,NS,malignant melanoma,superficial spreading c.4646C>T p.A1549V 6
17 COSM231666 PREX2 skin,NS,malignant melanoma,nodular c.4669C>T p.R1557C 6
18 COSM231627 PREX2 skin,NS,malignant melanoma,superficial spreading c.34G>T p.E12* 6
19 COSM231662 PREX2 skin,NS,malignant melanoma,nodular c.4127C>T p.A1376V 6
20 COSM3650433 PREX2 skin,NS,malignant melanoma,superficial spreading c.984G>A p.W328* 6
21 COSM231655 PREX2 skin,NS,malignant melanoma,superficial spreading c.2531G>A p.G844D 6
22 COSM580 NRAS skin,NS,malignant melanoma,nodular c.181C>A p.Q61K 6
23 COSM583 NRAS skin,NS,malignant melanoma,superficial spreading c.182A>T p.Q61L 6
24 COSM584 NRAS skin,NS,malignant melanoma,nodular c.182A>G p.Q61R 6
25 COSM563 NRAS skin,NS,malignant melanoma,nodular c.34G>A p.G12S 6
26 COSM564 NRAS skin,NS,malignant melanoma,nodular c.35G>A p.G12D 6
27 COSM574 NRAS skin,NS,malignant melanoma,nodular c.38G>T p.G13V 6
28 COSM577 NRAS skin,NS,malignant melanoma,superficial spreading c.52G>A p.A18T 6
29 COSM569 NRAS skin,NS,malignant melanoma,nodular c.37G>C p.G13R 6
30 COSM582 NRAS skin,NS,malignant melanoma,superficial spreading c.182A>C p.Q61P 6
31 COSM566 NRAS skin,NS,malignant melanoma,nodular c.35G>T p.G12V 6
32 COSM573 NRAS skin,NS,malignant melanoma,superficial spreading c.38G>A p.G13D 6
33 COSM586 NRAS skin,NS,malignant melanoma,nodular c.183A>C p.Q61H 6
34 COSM585 NRAS skin,NS,malignant melanoma,nodular c.183A>T p.Q61H 6
35 COSM561 NRAS skin,NS,malignant melanoma,superficial spreading c.34G>C p.G12R 6
36 COSM43344 NRAS skin,NS,malignant melanoma,superficial spreading c.203G>C p.R68T 6
37 COSM581 NRAS skin,NS,malignant melanoma,nodular c.181C>G p.Q61E 6
38 COSM3724522 NRAS skin,NS,malignant melanoma,superficial spreading c.184G>C p.E62Q 6
39 COSM5049808 NF1 skin,NS,malignant melanoma,nodular c.3652C>T p.Q1218* 6
40 COSM6503458 NF1 skin,NS,malignant melanoma,superficial spreading c.5531A>C p.K1844T 6
41 COSM6503455 NF1 skin,NS,malignant melanoma,superficial spreading c.2131C>T p.R711C 6
42 COSM5049807 NF1 skin,NS,malignant melanoma,nodular c.3097C>T p.Q1033* 6
43 COSM3515852 NF1 skin,NS,malignant melanoma,nodular c.3208C>T p.Q1070* 6
44 COSM5049809 NF1 skin,NS,malignant melanoma,nodular c.3239T>A p.L1080Q 6
45 COSM1756934 NF1 skin,NS,malignant melanoma,nodular c.3028C>T p.Q1010* 6
46 COSM25914 MLH1 skin,NS,malignant melanoma,nodular c.1732-1G>A p.? 6
47 COSM235617 MAP2K1 skin,NS,malignant melanoma,nodular c.1144A>C p.N382H 6
48 COSM521 KRAS skin,NS,malignant melanoma,superficial spreading c.35G>A p.G12D 6
49 COSM553 KRAS skin,NS,malignant melanoma,nodular c.182A>T p.Q61L 6
50 COSM520 KRAS skin,NS,malignant melanoma,superficial spreading c.35G>T p.G12V 6

Copy number variations for Melanoma from CNVD:

7 (show top 50) (show all 1973)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13791 1 1 46500000 Insertion Melanoma
2 13897 1 1007060 1041599 Amplification C1orf159 Melanoma
3 14968 1 111600000 148000000 Deletion Melanoma
4 15008 1 111800000 116100000 Gain NRAS Melanoma
5 15387 1 115048600 115061038 Gain NRAS Melanoma
6 18715 1 147200000 149200000 Ampfication SETDB1 Melanoma
7 20086 1 15300000 247249719 Insertion Melanoma
8 21281 7 92072170 92303813 Gain CDK6 Malignant melanoma
9 24543 1 182188599 196365692 Amplification ASPM Melanoma
10 24544 1 182188599 196365692 Amplification ATP6V1G3 Melanoma
11 24545 1 182188599 196365692 Amplification B3GALT2 Melanoma
12 24546 1 182188599 196365692 Amplification C1orf27 Melanoma
13 24547 1 182188599 196365692 Amplification C1orf53 Melanoma
14 24548 1 182188599 196365692 Amplification C1orf99 Melanoma
15 24549 1 182188599 196365692 Amplification CDC73 Melanoma
16 24550 1 182188599 196365692 Amplification CFH Melanoma
17 24551 1 182188599 196365692 Amplification CFHR1 Melanoma
18 24552 1 182188599 196365692 Amplification CFHR2 Melanoma
19 24553 1 182188599 196365692 Amplification CFHR3 Melanoma
20 24554 1 182188599 196365692 Amplification CFHR4 Melanoma
21 24555 1 182188599 196365692 Amplification CFHR5 Melanoma
22 24556 1 182188599 196365692 Amplification CRB1 Melanoma
23 24557 1 182188599 196365692 Amplification DENND1B Melanoma
24 24558 1 182188599 196365692 Amplification F13B Melanoma
25 24559 1 182188599 196365692 Amplification FAM5C Melanoma
26 24560 1 182188599 196365692 Amplification GLRX2 Melanoma
27 24561 1 182188599 196365692 Amplification HMCN1 Melanoma
28 24562 1 182188599 196365692 Amplification KCNT2 Melanoma
29 24563 1 182188599 196365692 Amplification LHX9 Melanoma
30 24564 1 182188599 196365692 Amplification NEK7 Melanoma
31 24565 1 182188599 196365692 Amplification OCLM Melanoma
32 24566 1 182188599 196365692 Amplification PDC Melanoma
33 24567 1 182188599 196365692 Amplification PLA2G4A Melanoma
34 24568 1 182188599 196365692 Amplification PRG4 Melanoma
35 24569 1 182188599 196365692 Amplification PTGS2 Melanoma
36 24570 1 182188599 196365692 Amplification PTPRC Melanoma
37 24571 1 182188599 196365692 Amplification RGS1 Melanoma
38 24572 1 182188599 196365692 Amplification RGS13 Melanoma
39 24573 1 182188599 196365692 Amplification RGS18 Melanoma
40 24574 1 182188599 196365692 Amplification RGS2 Melanoma
41 24575 1 182188599 196365692 Amplification RGS21 Melanoma
42 24576 1 182188599 196365692 Amplification TPR Melanoma
43 24577 1 182188599 196365692 Amplification TROVE2 Melanoma
44 24578 1 182188599 196365692 Amplification UCHL5 Melanoma
45 24579 1 182188599 196365692 Amplification ZBTB41 Melanoma
46 26238 1 198304656 198310281 Deletion Melanoma
47 29172 1 228366540 228914590 LOH Melanoma
48 29295 1 2300000 46500000 Insertion Melanoma
49 29296 1 2300000 46500000 Insertion Melanoma
50 30306 1 241700000 247249719 Insertion Melanoma

Expression for Melanoma

Search GEO for disease gene expression data for Melanoma.

Pathways for Melanoma

Pathways related to Melanoma according to KEGG:

36
# Name Kegg Source Accession
1 Melanoma hsa05218

Pathways related to Melanoma according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.01 BRAF FBN1 KIT MAP2K1 NRAS PTEN
2
Show member pathways
12.81 BRAF GNAQ KIT MAP2K1 NRAS
3
Show member pathways
12.81 BRAF CDK4 CDKN2A KIT MAP2K1 MITF
4
Show member pathways
12.68 BRAF GNAQ KIT MAP2K1 NRAS
5
Show member pathways
12.66 BRAF MAGED1 MAP2K1 NRAS PTEN
6
Show member pathways
12.47 BRAF CDK4 CDKN2A KIT MAP2K1 NRAS
7
Show member pathways
12.46 BRAF CDK4 CDKN2A GNAQ MAP2K1 NRAS
8
Show member pathways
12.43 BRAF MAP2K1 NRAS PTEN
9
Show member pathways
12.32 BRAF MAP2K1 NRAS PTEN
10
Show member pathways
12.3 GNAQ KIT MAP2K1 MITF NRAS
12
Show member pathways
12.2 BRAF MAP2K1 MITF NRAS
13
Show member pathways
12.17 BRAF CDK4 MAP2K1 NRAS PTEN
14
Show member pathways
12.14 BRAF GNAQ MAP2K1 NRAS
15
Show member pathways
12.12 KIT MAP2K1 MITF PTEN
16
Show member pathways
12.04 BRAF MAP2K1 NRAS PTEN
17 12.03 CDK4 CDKN2A MAP2K1 NRAS PTEN
18 12 BRAF CDK4 CDKN2A GNAQ KIT MAP2K1
19 11.95 GNAQ MAP2K1 NRAS PTEN
20
Show member pathways
11.95 BRAF CDK4 CDKN2A MAP2K1 NRAS
21 11.92 BRAF GNAQ MAP2K1 NRAS
22 11.91 BRAF GNAQ MAP2K1 NRAS
23 11.87 BRAF CDKN2A MAP2K1 PTEN
24 11.81 BRAF GNAQ MAP2K1
25 11.78 GNAQ MAP2K1 NRAS
26
Show member pathways
11.74 BRAF KIT MAP2K1 NRAS
27 11.63 BRAF CDK4 GNAQ MAP2K1
28
Show member pathways
11.61 BRAF MAP2K1 NRAS
29 11.59 KIT MAP2K1 NRAS PTEN
30 11.48 BRAF GNAQ MAP2K1 NRAS
31 11.48 BRAF CDK4 CDKN2A MAP2K1 NRAS PTEN
32 11.42 BRAF CDK4 CDKN2A MAP2K1 NRAS
33 11.4 BRAF MAP2K1 NRAS
34 11.29 BRAF MAP2K1 NRAS
35 10.99 GNAQ MAP2K1 NRAS

GO Terms for Melanoma

Biological processes related to Melanoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.8 BRAF KIT MAP2K1 NRAS
2 regulation of cell proliferation GO:0042127 9.73 BRAF CDK4 KIT MITF
3 heart development GO:0007507 9.71 FBN1 GNAQ MAP2K1 PTEN
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.56 BRAF GPNMB MAP2K1 PTEN
5 developmental pigmentation GO:0048066 9.48 GNAQ KIT
6 maternal behavior GO:0042711 9.46 GNAQ PTEN
7 positive regulation of gene expression GO:0010628 9.43 BRAF CDKN2A KIT MAP2K1 MITF PTEN
8 somatic stem cell division GO:0048103 9.37 CDKN2A KIT
9 cellular response to insulin-like growth factor stimulus GO:1990314 9.32 FBN1 PTEN
10 myeloid progenitor cell differentiation GO:0002318 9.16 BRAF KIT
11 regulation of axon regeneration GO:0048679 8.8 BRAF MAP2K1 PTEN

Molecular functions related to Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.89 BRAF CDK4 CDKN2A FBN1 GNAQ GPNMB
2 nucleotide binding GO:0000166 9.02 BRAF CDK4 KIT MAP2K1 NRAS

Sources for Melanoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....